Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

R3767-ONC-2055

A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma (NCT05608291)

No longer recruiting

R3ACT-R

A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantation (R3ACT Randomised (R3R)) (ACTRN12620000171910p)

Currently recruiting

R5458-ONC-2246

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma [LINKER-MM5] (NCT07222761)

A study to compare linvoseltamab monotherapy and linvoseltamab + carfilzomib combination therapy with standard-of-care combination regimens in participants with relapsed/refractory multiple myeloma (RRMM).
Coming soon

Rainbow Trial [RAY902CT]

PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)

The RAY902CT study is designed to evaluate the safety and efficacy of RAY121 in adult participants with Bullous Pemphigoid (BP) or Behcet’s syndrome.  Participants receive trial medication via a monthly injection under the skin (subcutaneous). The treatment period will be approximately 12 weeks with the option of a long-term extension.

Currently recruiting

RAPID STUDY

A multi-centre, pRospective, safety and efficacy evaluation study on Automated external defibrillation in PatIents with CellAED (ACTRN12621000258853)

No longer recruiting

RASolve 301

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (NCT06881784)

Global, open-label, Phase 3 study, patients with locally advanced or metastatic RAS-mutant NSCLC will be randomized to RMC-6236 or docetaxel (in a 1:1 ratio) on a 21-day treatment cycle.
Currently recruiting

RATIONALISE

RATIONALISE - Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (TRU-RLS-21) (ACTRN12622000359730)

Currently recruiting

REBUILD-SM

A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (ACTRN12623001133628)

Currently recruiting

ReCAPS

Recovery-focused Community support to Avoid readmissions and improve participation after Stroke (ACTRN12618001468213)

Currently recruiting

REDEEM

REDEEM: A randomised controlled trial of VV ECMO to de-sedate, extubate, and mobilise in hypoxic respiratory failure. (NCT05562505)

Currently recruiting

REFORM

Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)

Currently recruiting

Regeneron

A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In Combination With Linvoseltamab, An Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, In Participants With Relapsed/Refractory Multiple Myeloma. (NCT06669247)

Currently recruiting

RELATIVITY-127

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma (NCT05625399)

No longer recruiting

REMAP_CAP

Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)

Currently recruiting

RENAL BX

A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)

Currently recruiting

RESOLUTE

A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to very severe chronic obstructive pulmonary disease (COPD) wiht a history of frequent COPD exacerbations and elevated peripheral blood eosinophils. (RESOLUTE) (NCT04053634)

No longer recruiting

RESPIR-102

A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Lung Infection (NCT06016088)

Currently recruiting

RESPOCT-ED Study

RESpiratory pathogen Point-Of-Care Testing in Emergency Departments (ACTRN12625000123448)

Currently recruiting

RESPONDER-HF

Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved EF Heart Failure (RESPONDER-HF) (NCT05425459)

Currently recruiting

RETHINK-ALZ

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-moderate Alzheimer’s Disease (NCT04994483)

Currently recruiting
22 23 24 25 26